Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology · Pancreatic Neuroendocrine Tumor

Genetics & Hereditary Syndromes

At a Glance

While most pancreatic neuroendocrine tumors (pNETs) occur by chance, many are linked to hereditary syndromes like MEN1 and VHL. Identifying a genetic mutation through testing can significantly alter your surgical strategy, open up targeted treatment options, and help protect family members.

While most pancreatic neuroendocrine tumors (pNETs) are “sporadic” (meaning they occur by chance), a significant number are linked to hereditary genetic syndromes [1][2]. Because these genetic links have a major impact on how you are treated and how your family is monitored, genetic counseling is often a standard part of the initial pNET workup [3][4].

The MEN1 Connection

The most common hereditary cause of pNETs is Multiple Endocrine Neoplasia type 1 (MEN1) [1]. This syndrome is caused by a mutation in the MEN1 gene, which normally helps prevent tumors from forming [5].

If you have MEN1, your pNETs will behave differently than sporadic tumors:

  • Multifocality: Instead of one single tumor, patients with MEN1 often develop many small tumors throughout the entire pancreas [6][7].
  • The “Three Ps”: MEN1 often affects three specific areas: the Parathyroid glands (which control calcium), the Pituitary gland (at the base of the brain), and the Pancreas [1].
  • Early Onset: These tumors often appear at a younger age than sporadic pNETs [2].

Von Hippel-Lindau (VHL) Syndrome

Von Hippel-Lindau (VHL) is another syndrome that can lead to pNETs [1]. While VHL is more commonly associated with kidney tumors and growths in the eyes or brain, up to 15% of people with VHL will develop pNETs [5]. These tumors are usually non-functional (don’t produce hormones) and often grow very slowly, sometimes allowing for long periods of monitoring before surgery is needed [7][8].

Why Genetic Testing Matters

Identifying a hereditary syndrome changes your medical roadmap in several critical ways:

  1. Surgical Strategy: In sporadic cases, the goal is often to remove the single tumor. In MEN1, because there are often many tumors and a high risk of new ones forming later, surgeons try to be organ-sparing [6]. They may use techniques like enucleation (removing only the tumor “nugget”) to save as much of the healthy, insulin-producing pancreas as possible [9][10].
  2. Lifelong Surveillance: A hereditary diagnosis means you will need regular, lifelong “check-ups” using scans like SSTR PET/CT to monitor not just your pancreas, but other vulnerable glands like the parathyroid [11][12].
  3. Family Protection: If a mutation is found, your siblings and children can be tested [3]. This allows them to start screening early, often catching tumors when they are small and most manageable.
  4. Targeted Treatments: Some research suggests that patients with MEN1 or VHL may respond particularly well to certain treatments, like the targeted drug everolimus or HIF-2α inhibitors, providing more options for managing advanced disease [13][14].

Even if you have no family history of cancer, current research suggests that many pNET patients carry “hidden” genetic mutations that only a specialized test can find [4]. Understanding your genetic makeup is a powerful tool for tailoring your care to your specific biology [3].

Common questions in this guide

Do I need genetic testing if I have a pancreatic neuroendocrine tumor?
While most pNETs occur by chance, a significant number are linked to hereditary genetic syndromes. Because finding a genetic link can drastically change your treatment plan and family screening needs, genetic counseling is now a standard part of the initial diagnostic workup.
What is the connection between MEN1 and pNETs?
MEN1 is the most common hereditary cause of pNETs. Unlike sporadic cases, patients with MEN1 often develop multiple small tumors throughout the pancreas and may also develop growths in their parathyroid and pituitary glands.
How does having a genetic syndrome change the surgical approach for a pNET?
If you have a hereditary syndrome, you are at a higher risk of developing new tumors over time. To preserve your long-term health, surgeons often prefer organ-sparing techniques, such as removing only the tumors themselves, rather than removing large sections of your healthy pancreas.
What is VHL syndrome and how does it affect the pancreas?
Von Hippel-Lindau (VHL) syndrome is a genetic condition that increases the risk of certain tumors. Up to 15% of people with VHL will develop pNETs, which are usually slow-growing and non-functional, meaning they don't produce excess hormones.
Should my children or siblings be tested for genetic mutations?
If you test positive for a hereditary mutation like MEN1 or VHL, your parents, siblings, and children may also carry the gene. Testing allows them to start specialized cancer screening early, catching potential tumors when they are small and highly manageable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pNET diagnosis, should I be referred for genetic counseling and testing?
  2. 2.Does my tumor appear 'multifocal' (multiple tumors) on imaging, and what does that mean for my genetic risk?
  3. 3.If I have MEN1, how will our surgical strategy change to preserve my pancreatic function over my lifetime?
  4. 4.Are there other organs, such as the parathyroid or pituitary glands, that we should be screening now?
  5. 5.Should my children or siblings be tested for the same genetic mutations?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Genetics of Pancreatic Neuroendocrine Tumors.

    Mohindroo C, McAllister F, De Jesus-Acosta A

    Hematology/oncology clinics of North America 2022; (36(5)):1033-1051 doi:10.1016/j.hoc.2022.07.005.

    PMID: 36154786
  2. 2

    Overview of Genetically Determined Diseases/Multiple Endocrine Neoplasia Syndromes Predisposing to Endocrine Tumors.

    Decmann A, Patócs A, Igaz P

    Experientia supplementum (2012) 2019; (111()):105-127 doi:10.1007/978-3-030-25905-1_7.

    PMID: 31588530
  3. 3

    Surgical management of pancreatic neuroendocrine tumors: an introduction.

    Hain E, Sindayigaya R, Fawaz J, et al.

    Expert review of anticancer therapy 2019; (19(12)):1089-1100 doi:10.1080/14737140.2019.1703677.

    PMID: 31825691
  4. 4

    Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

    De Jesus-Acosta A, Mohindroo C

    JCO precision oncology 2024; (8()):e2400221 doi:10.1200/PO.24.00221.

    PMID: 39231376
  5. 5

    Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.

    Ishida H, Lam AK

    Critical reviews in oncology/hematology 2022; (172()):103648 doi:10.1016/j.critrevonc.2022.103648.

    PMID: 35248713
  6. 6

    Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort.

    van Beek DJ, Nell S, Vorselaars WMCM, et al.

    Annals of surgical oncology 2021; (28(8)):4387-4399 doi:10.1245/s10434-020-09496-1.

    PMID: 33521900
  7. 7

    Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

    Qiu W, Christakis I, Silva A, et al.

    Clinical endocrinology 2016; (85(3)):400-7 doi:10.1111/cen.13119.

    PMID: 27256431
  8. 8

    Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.

    Kamilaris CDC, Stratakis CA

    Frontiers in endocrinology 2019; (10()):339 doi:10.3389/fendo.2019.00339.

    PMID: 31263451
  9. 9

    Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1.

    Albers MB, Manoharan J, Bollmann C, et al.

    World journal of surgery 2019; (43(2)):552-558 doi:10.1007/s00268-018-4809-1.

    PMID: 30288555
  10. 10

    Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1.

    Lopez CL, Albers MB, Bollmann C, et al.

    World journal of surgery 2016; (40(7)):1729-36 doi:10.1007/s00268-016-3456-7.

    PMID: 26956903
  11. 11

    Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.

    Mennetrey C, Le Bras M, Bando-Delaunay A, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(5)):e2056-e2064 doi:10.1210/clinem/dgab891.

    PMID: 34940846
  12. 12

    Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

    Lastoria S, Marciello F, Faggiano A, et al.

    Endocrine 2016; (52(3)):488-94 doi:10.1007/s12020-015-0702-y.

    PMID: 26242621
  13. 13

    The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.

    Nuñez JE, Donadio M, Filho DR, et al.

    Journal of gastrointestinal oncology 2019; (10(4)):645-651 doi:10.21037/jgo.2019.01.33.

    PMID: 31392045
  14. 14

    Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports.

    Mowrey K, Northrup H, Rougeau P, et al.

    Frontiers in neurology 2021; (12()):627672 doi:10.3389/fneur.2021.627672.

    PMID: 33897589

This page explains pNET genetics and hereditary syndromes for educational purposes only. Always consult your oncologist or a certified genetic counselor to discuss genetic testing for you and your family.

Get notified when new evidence is published on Neuroendocrine tumor of pancreas.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.